- Arcus Biosciences (RCUS, Financial) grants stock options and restricted stock units to new employees.
- The stock options cover 16,960 shares at $7.04 per share, the closing price on April 8, 2025.
- These grants are part of the company’s 2020 Inducement Plan under NYSE Rule 303A.08.
Arcus Biosciences (RCUS), a clinical-stage biopharmaceutical company specializing in cancer therapies, has announced the issuance of equity awards to six new employees. The company’s Compensation Committee has approved stock options for a total of 16,960 shares. These options are priced at $7.04 per share, equivalent to the closing price on April 8, 2025.
In addition to the stock options, the new employees have been granted restricted stock units (RSUs) totaling 8,530 shares. These equity awards were made under Arcus Biosciences’ 2020 Inducement Plan, a strategic initiative established in January 2020, aligning with the inducement exception stipulated by the NYSE Listed Company Manual Rule 303A.08.
Arcus Biosciences continues to advance its portfolio of cancer therapies globally, collaborating with industry partners to develop first- or best-in-class medicines targeted at well-characterized biological pathways. The company’s efforts are focused on creating innovative combination therapies that aim to provide significant benefits to cancer patients.
